MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598251 | Name: Lamivudine, (+/-)-trans-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lamivudine, (+/-)-trans- is a reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Chemical Structure

Lamivudine, (+/-)-trans-
Lamivudine, (+/-)-trans-
CAS#131086-22-1 (±-trans)

Theoretical Analysis

MedKoo Cat#: 598251

Name: Lamivudine, (+/-)-trans-

CAS#: 131086-22-1 (±-trans)

Chemical Formula: C8H11N3O3S

Exact Mass: 229.0521

Molecular Weight: 229.25

Elemental Analysis: C, 41.91; H, 4.84; N, 18.33; O, 20.94; S, 13.98

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
134678-17-4 160552-55-6 (sulfoxide) 160552-54-5 (R-sulfoxide) 131086-22-1 (±-trans)
Synonym
Lamivudine, (+/-)-trans-; Lamivudine specified impurity B;
IUPAC/Chemical Name
4-amino-1-((2S,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
InChi Key
JTEGQNOMFQHVDC-BQBZGAKWSA-N
InChi Code
InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m0/s1
SMILES Code
O=C1N=C(N)C=CN1[C@@H]2CS[C@@H](CO)O2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 229.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Heipertz RA Jr, Miller TG, Kelley CM, Delaney WE 4th, Locarnini SA, Isom HC. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication. J Virol. 2007 Apr;81(7):3068-76. Epub 2007 Jan 10. PubMed PMID: 17215289; PubMed Central PMCID: PMC1866076. 2: Xie Y, Liu Q, Wang CH, Tang CW. [Inhibition of transcription and expression of X gene by lamivudine]. Zhonghua Gan Zang Bing Za Zhi. 2005 Jan;13(1):27-30. Chinese. PubMed PMID: 15670487. 3: Bottecchia M, Ikuta N, Niel C, Araujo NM, O KM, Gomes SA. Lamivudine resistance and other mutations in the polymerase and surface antigen genes of hepatitis B virus associated with a fatal hepatic failure case. J Gastroenterol Hepatol. 2008 Jan;23(1):67-72. doi: 10.1111/j.1440-1746.2007.05238.x. PubMed PMID: 18171343. 4: Luo YY, Tao Y, Cai XF, Zhang WL, Long QX, Guo H, Huang AL, Hu JL. A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation. Antiviral Res. 2016 Feb;126:99-107. doi: 10.1016/j.antiviral.2015.12.009. Epub 2015 Dec 29. PubMed PMID: 26738784. 5: Cheng AS, Chan HL, Leung WK, To KF, Go MY, Chan JY, Liew CT, Sung JJ. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol. 2004 Oct;17(10):1169-79. PubMed PMID: 15218507. 6: Xie Y, Tang CW, Wang CH. [Effect of HBV X gene transfection on octreotide-inhibited growth of hepatocellular carcinoma cell line HepG2]. Ai Zheng. 2005 Aug;24(8):965-9. Chinese. PubMed PMID: 16086874. 7: Steinberg JL, Yeo W, Zhong S, Chan JY, Tam JS, Chan PK, Leung NW, Johnson PJ. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol. 2000 Mar;60(3):249-55. PubMed PMID: 10630955. 8: Lenci I, Tariciotti L, Baiocchi L, Manzia TM, Toti L, Craboledda P, Callea F, Angelico M, Tisone G. Primary yolk sac tumor of the liver: incidental finding in a patient transplanted for hepatocellular carcinoma. Transpl Int. 2008 Jun;21(6):598-601. doi: 10.1111/j.1432-2277.2008.00667.x. Epub 2008 Mar 18. PubMed PMID: 18363574. 9: Janssen HL, Higuchi H, Abdulkarim A, Gores GJ. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol. 2003 Sep;39(3):414-20. PubMed PMID: 12927928. 10: Litwin S, Toll E, Jilbert AR, Mason WS. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol. 2005 Dec;34 Suppl 1:S96-S107. PubMed PMID: 16461233. 11: Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999 Jan;36(1):41-66. Review. PubMed PMID: 9989342. 12: Coffin CS, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP, Michalak TI, Terrault NA. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat. 2011 Jun;18(6):415-23. doi: 10.1111/j.1365-2893.2010.01321.x. PubMed PMID: 20626626; PubMed Central PMCID: PMC4142495. 13: Ugliarolo EA, Gagey D, Lantaño B, Moltrasio GY, Campos RH, Cavallaro LV, Moglioni AG. Synthesis and biological evaluation of novel homochiral carbocyclic nucleosides from 1-amino-2-indanols. Bioorg Med Chem. 2012 Oct 1;20(19):5986-91. doi: 10.1016/j.bmc.2012.07.028. Epub 2012 Jul 25. PubMed PMID: 22944333. 14: Pár A. [Hepatitis B virus (HBV) infection and hepatocarcinogenesis]. Orv Hetil. 2010 Jun 27;151(26):1045-53. doi: 10.1556/OH.2010.28881. Review. Hungarian. PubMed PMID: 20558351. 15: Rowland A, Mackenzie PI, Miners JO. Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition. Drug Metab Dispos. 2015 Jan;43(1):147-53. doi: 10.1124/dmd.114.060509. Epub 2014 Nov 7. PubMed PMID: 25380805. 16: Rodriguez-Frías F, Tabernero D, Quer J, Esteban JI, Ortega I, Domingo E, Cubero M, Camós S, Ferrer-Costa C, Sánchez A, Jardí R, Schaper M, Homs M, Garcia-Cehic D, Guardia J, Esteban R, Buti M. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One. 2012;7(5):e37874. doi: 10.1371/journal.pone.0037874. Epub 2012 May 30. PubMed PMID: 22666402; PubMed Central PMCID: PMC3364280.